Suppr超能文献

超声一维和二维测量预测乳腺癌患者新辅助化疗良好病理反应的准确性。

Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.

机构信息

Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, UK.

出版信息

Breast Cancer Res Treat. 2011 Jun;127(2):459-69. doi: 10.1007/s10549-011-1454-x. Epub 2011 Mar 25.

Abstract

Pathological complete response (pCR) is an important predictor of long-term survival in patients with breast cancer receiving neoadjuvant chemotherapy (NAC). At present, the accuracy of traditional radiological assessments during treatment in predicting pCR is poor. Unidimensional and 3D volumetric ultrasound measurements prior to, after 4 cycles (mid-treatment), and at the end of 8 cycles (end-treatment) of chemotherapy were available from a subset of 55 patients enrolled in Neo-tAnGo, a National Cancer Research Network (NCRN) UK neoadjuvant chemotherapy breast cancer trial. Proportional changes in longest diameter (LD) and volume as well as absolute residual size thresholds were examined for their ability to predict pCR or pCR plus minimal residual disease (pCR/MRD). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) and likelihood ratios (LRs) were calculated. Receiver-operator characteristic (ROC) curves and logistic regression models were also constructed. At mid-treatment, neither complete radiological response, nor proportional LD or volume changes were found predictive of final pCR. A small residual tumour volume (≤ 1 cm³ vs. > 1 cm³) at mid-treatment, however, was associated with pCR/MRD (P = 0.014). Sensitivity, specificity, PPV, NPV, LR+ and LR- values were 61%, 77%, 61%, 77%, 2.62 and 0.51, respectively. The area under the ROC curve was 0.689 (P = 0.03). Volume ≤ 1 cm³ at mid-treatment was found significant in a logistic regression (OR: 0.194, P = 0.011). At end-treatment, no ultrasound measurements were found predictive of pCR or pCR/MRD. In conclusion, proportional tumour size changes (the basis of the RECIST criteria) were not found predictive of good pathological response, although residual volume ≤ 1 cm³ at mid-treatment was found to be predictive of pCR/MRD. However, multiple volume and LD thresholds were examined and uncorrected P values presented, increasing the possibility of type I errors. Replication in an independent dataset is required.

摘要

病理完全缓解(pCR)是接受新辅助化疗(NAC)的乳腺癌患者长期生存的重要预测指标。目前,治疗过程中传统影像学评估预测 pCR 的准确性较差。在英国国家癌症研究网络(NCRN)新辅助化疗乳腺癌试验 Neo-tAnGo 中,有 55 名入组患者的亚组提供了化疗前、第 4 周期(中期)后、第 8 周期(末期)后的一维和三维体积超声测量值。最长直径(LD)和体积的比例变化以及绝对残留大小阈值被检查其预测 pCR 或 pCR 加最小残留疾病(pCR/MRD)的能力。计算了灵敏度、特异性、阳性预测值(PPV)和阴性预测值(NPV)以及似然比(LR)。还绘制了接收器操作特征(ROC)曲线和逻辑回归模型。在中期,完全的放射学反应,以及 LD 或体积的比例变化都不能预测最终的 pCR。然而,中期较小的残余肿瘤体积(≤1cm³ 与 >1cm³)与 pCR/MRD 相关(P = 0.014)。灵敏度、特异性、PPV、NPV、LR+和 LR-值分别为 61%、77%、61%、77%、2.62 和 0.51。ROC 曲线下面积为 0.689(P = 0.03)。中期体积≤1cm³在逻辑回归中是显著的(OR:0.194,P = 0.011)。在末期,没有超声测量值可以预测 pCR 或 pCR/MRD。总之,肿瘤大小的比例变化(RECIST 标准的基础)不能预测良好的病理反应,尽管中期残留体积≤1cm³被发现与 pCR/MRD 相关。然而,研究检查了多个体积和 LD 阈值,并呈现了未校正的 P 值,增加了 I 型错误的可能性。需要在独立数据集进行复制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验